PortalPublikationenExtracorporeal light chain elimination: high cut-off (HCO) h...

Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury

Standard

Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. / Heyne, Nils; Denecke, Barbara; Guthoff, Martina; Oehrlein, Katharina; Kanz, Lothar; Häring, Hans-Ulrich; Weisel, Katja C.

in: ANN HEMATOL, Jahrgang 91, Nr. 5, 05.2012, S. 729-735.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Heyne, N, Denecke, B, Guthoff, M, Oehrlein, K, Kanz, L, Häring, H-U & Weisel, KC 2012, 'Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury', ANN HEMATOL, Jg. 91, Nr. 5, S. 729-735. https://doi.org/10.1007/s00277-011-1383-0

APA

Heyne, N., Denecke, B., Guthoff, M., Oehrlein, K., Kanz, L., Häring, H-U., & Weisel, K. C. (2012). Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. ANN HEMATOL, 91(5), 729-735. https://doi.org/10.1007/s00277-011-1383-0

Vancouver

Heyne N, Denecke B, Guthoff M, Oehrlein K, Kanz L, Häring H-U et al. Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. ANN HEMATOL. 2012 Mai;91(5):729-735. https://doi.org/10.1007/s00277-011-1383-0

Bibtex

@article{2b1339297a784bfeaa34489e2d547b2d,
title = "Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury",
abstract = "Acute kidney injury (AKI) is frequent in multiple myeloma (MM) patients and strongly affects prognosis, with particularly poor outcomes in patients requiring hemodialysis. Introduction of the novel therapeutic agents to MM therapy has improved myeloma response and renal outcome. This case series reviews the efficacy of combined systemic and extracorporeal therapy to further optimize time to light chain (serum-free light chain (sFLC)) reduction and renal recovery in MM patients with dialysis-dependent AKI (n = 19). High cut-off (HCO) hemodialysis for extracorporeal sFLC removal was initiated in parallel to chemotherapy. Combined therapy resulted in early sFLC response after a median of 13 (range 4-48) days and 6 (3-22) HCO hemodialysis sessions. Time to sFLC response was shorter in patients recovering renal function. Median time to dialysis independence was 15 (4-64) days. By intent-to-treat analysis, sustained renal recovery was achieved in 73.7% (77.8% adjusted for death) of patients. In multivariate analysis, duration of AKI prior to initiation of therapy was an independent predictor of renal functional outcome. Combining HCO hemodialysis for extracorporeal sFLC elimination and effective chemotherapy is a novel treatment strategy allowing for early and sustained sFLC reduction and a high proportion of renal recovery in these patients. Timely diagnosis and onset of therapy is essential for improving renal outcome.",
keywords = "Acute Kidney Injury, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Immunoglobulin Light Chains, Male, Middle Aged, Multiple Myeloma, Prognosis, Reference Values, Renal Dialysis, Treatment Outcome, Journal Article",
author = "Nils Heyne and Barbara Denecke and Martina Guthoff and Katharina Oehrlein and Lothar Kanz and Hans-Ulrich H{\"a}ring and Weisel, {Katja C}",
year = "2012",
month = may,
doi = "10.1007/s00277-011-1383-0",
language = "English",
volume = "91",
pages = "729--735",
journal = "ANN HEMATOL",
issn = "0939-5555",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury

AU - Heyne, Nils

AU - Denecke, Barbara

AU - Guthoff, Martina

AU - Oehrlein, Katharina

AU - Kanz, Lothar

AU - Häring, Hans-Ulrich

AU - Weisel, Katja C

PY - 2012/5

Y1 - 2012/5

N2 - Acute kidney injury (AKI) is frequent in multiple myeloma (MM) patients and strongly affects prognosis, with particularly poor outcomes in patients requiring hemodialysis. Introduction of the novel therapeutic agents to MM therapy has improved myeloma response and renal outcome. This case series reviews the efficacy of combined systemic and extracorporeal therapy to further optimize time to light chain (serum-free light chain (sFLC)) reduction and renal recovery in MM patients with dialysis-dependent AKI (n = 19). High cut-off (HCO) hemodialysis for extracorporeal sFLC removal was initiated in parallel to chemotherapy. Combined therapy resulted in early sFLC response after a median of 13 (range 4-48) days and 6 (3-22) HCO hemodialysis sessions. Time to sFLC response was shorter in patients recovering renal function. Median time to dialysis independence was 15 (4-64) days. By intent-to-treat analysis, sustained renal recovery was achieved in 73.7% (77.8% adjusted for death) of patients. In multivariate analysis, duration of AKI prior to initiation of therapy was an independent predictor of renal functional outcome. Combining HCO hemodialysis for extracorporeal sFLC elimination and effective chemotherapy is a novel treatment strategy allowing for early and sustained sFLC reduction and a high proportion of renal recovery in these patients. Timely diagnosis and onset of therapy is essential for improving renal outcome.

AB - Acute kidney injury (AKI) is frequent in multiple myeloma (MM) patients and strongly affects prognosis, with particularly poor outcomes in patients requiring hemodialysis. Introduction of the novel therapeutic agents to MM therapy has improved myeloma response and renal outcome. This case series reviews the efficacy of combined systemic and extracorporeal therapy to further optimize time to light chain (serum-free light chain (sFLC)) reduction and renal recovery in MM patients with dialysis-dependent AKI (n = 19). High cut-off (HCO) hemodialysis for extracorporeal sFLC removal was initiated in parallel to chemotherapy. Combined therapy resulted in early sFLC response after a median of 13 (range 4-48) days and 6 (3-22) HCO hemodialysis sessions. Time to sFLC response was shorter in patients recovering renal function. Median time to dialysis independence was 15 (4-64) days. By intent-to-treat analysis, sustained renal recovery was achieved in 73.7% (77.8% adjusted for death) of patients. In multivariate analysis, duration of AKI prior to initiation of therapy was an independent predictor of renal functional outcome. Combining HCO hemodialysis for extracorporeal sFLC elimination and effective chemotherapy is a novel treatment strategy allowing for early and sustained sFLC reduction and a high proportion of renal recovery in these patients. Timely diagnosis and onset of therapy is essential for improving renal outcome.

KW - Acute Kidney Injury

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Female

KW - Humans

KW - Immunoglobulin Light Chains

KW - Male

KW - Middle Aged

KW - Multiple Myeloma

KW - Prognosis

KW - Reference Values

KW - Renal Dialysis

KW - Treatment Outcome

KW - Journal Article

U2 - 10.1007/s00277-011-1383-0

DO - 10.1007/s00277-011-1383-0

M3 - SCORING: Journal article

C2 - 22170517

VL - 91

SP - 729

EP - 735

JO - ANN HEMATOL

JF - ANN HEMATOL

SN - 0939-5555

IS - 5

ER -